Comparative Pharmacology
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus V CILLIN K.
UNIPEN IN PLASTIC CONTAINER vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic